Incyte Announces Japanese Approval of Pemazyre (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs) - Seite 4

Disclaimer

The drug information contained herein is intended for the disclosure of Incyte corporate information and is not intended to advertise or promote any medicinal product, including those under development.

^{____________________________
1} Overview of Orphan Drug/Medical Device Designation System. Ministry of Health, Labour and Welfare. Available at: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/o ...
² Pemazyre (pemigatinib) [Package Insert]. Wilmington, DE: Incyte; 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230326005073/en/

The Incyte Stock at the time of publication of the news with a fall of -0,50 % to 65,84EUR on Tradegate stock exchange (24. März 2023, 18:46 Uhr).